Oric Pharmaceuticals signs trial collaboration with Bayer for Nubeqa supply in Phase 3 prostate cancer study

Oric Pharmaceuticals entered a clinical trial collaboration and supply agreement with Bayer for the Himalayas-1 Phase 3 trial in mCRPC.

Bayer will supply Nubeqa (darolutamide) at no cost for use with rinzimetostat in the study.

Oric will sponsor and run the trial; Bayer receives no license, option, or rights to rinzimetostat.